公开(公告)号：US20240002368A1

公开(公告)日：2024-01-04

申请号：US18037965

申请日：2021-11-23

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Hailong Li ,  Wenge Zhong ,  Wei Huang

IPC: C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14

CPC classification number: C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula (I) a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof, for use in, e.g. treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20230278991A1

公开(公告)日：2023-09-07

申请号：US18113859

申请日：2023-02-24

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I)




and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20210179594A1

公开(公告)日：2021-06-17

申请号：US16950393

申请日：2020-11-17

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20230174512A1

公开(公告)日：2023-06-08

申请号：US17922804

申请日：2021-05-04

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: C07D401/14 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07D401/14 ,  A61K45/06 ,  A61P35/00

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US10954221B2

公开(公告)日：2021-03-23

申请号：US16902807

申请日：2020-06-16

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20200325121A1

公开(公告)日：2020-10-15

申请号：US16902807

申请日：2020-06-16

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Wei Guo

IPC: C07D405/14 ,  C07D471/04 ,  C07D417/14

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20240066031A1

公开(公告)日：2024-02-29

申请号：US18373060

申请日：2023-09-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D487/04

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D487/04

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20220389037A1

公开(公告)日：2022-12-08

申请号：US17624514

申请日：2020-07-03

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: C07F9/6561 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D519/00 ,  C07D491/107 ,  C07D487/04 ,  C07D473/32 ,  C07F9/6558 ,  C07D498/04 ,  A61K45/06

Abstract: Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.

公开(公告)号：US20220024901A1

公开(公告)日：2022-01-27

申请号：US17296078

申请日：2019-11-19

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong

IPC: C07D405/14 ,  C07D471/04 ,  C07D498/04 ,  C07D471/08

Abstract: Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

公开(公告)号：US20250042883A1

公开(公告)日：2025-02-06

申请号：US18830194

申请日：2024-09-10

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge ZHONG ,  Wei GUO

IPC: C07D405/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.